EAM
VKTX icon

Eagle Asset Management’s Viking Therapeutics VKTX Stock Holding History

Eagle Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,437
Closed -$3.62M – 605
2024
Q2 		$3.62M Sell
65,437
-215,411
-77% -$14.1M 0.02% 425
2024
Q1 		$22.3M Buy
280,848
+19,065
+7% +$848K 0.11% 176
2023
Q4 		$4.87M Buy
+261,783
New +$3.42M 0.03% 374
2018
Q4 		– Sell
-130,987
Closed -$2.28M – 632
2018
Q3 		$2.28M Buy
130,987
+53,076
+68% +$632K 0.01% 513
2018
Q2 		$739K Buy
+77,911
New +$518K ﹤0.01% 565

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Eagle Asset Management's VKTX Position: Q3 2024 in Review

Eagle Asset Management sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 65,437 shares — an estimated $3.62M sold.

Eagle Asset Management first reported a position in VKTX in Q2 2018 and held it in 5 quarters. The position peaked at $22.3M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Eagle Asset Management reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eagle Asset Management sold 65,437 Viking Therapeutics shares in Q3 2024, an estimated $3.62M.
  • Eagle Asset Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 5 quarters.
  • Eagle Asset Management's Viking Therapeutics position peaked at $22.3M in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.